FGG and integrin β2 bind to distinct binding sites in ICAM-1 [9, 59], shedding light on the possibility of exploiting neutralizing antibodies or compounds to specifically obstruct ICAM-1‒FGG interaction without affecting integrin β2‒ICAM-1 binding involved in anti-tumor immune responses. This evidence concerns the gene ICAM1 and neoplasm.